Immunome (NASDAQ:IMNM) Sets New 52-Week Low – What’s Next?

Immunome, Inc. (NASDAQ:IMNM) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $5.43 and last traded at $5.79, with a volume of 240742 shares changing hands. The stock had previously closed at $5.93.

Wall Street Analysts Forecast Growth

IMNM has been the topic of several research reports. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Lifesci Capital started coverage on Immunome in a report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target for the company. Lake Street Capital assumed coverage on shares of Immunome in a research note on Wednesday, April 2nd. They set a “buy” rating and a $23.00 price objective on the stock. Stephens restated an “overweight” rating and issued a $30.00 target price on shares of Immunome in a research note on Thursday, March 20th. Finally, Guggenheim cut their price objective on shares of Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, March 20th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $25.14.

Immunome Stock Up 11.7 %

The firm’s 50 day moving average is $8.72 and its two-hundred day moving average is $10.71. The stock has a market cap of $539.97 million, a price-to-earnings ratio of -0.77 and a beta of 2.05.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). The company had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. On average, analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Insider Activity

In related news, CEO Clay B. Siegall bought 150,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the transaction, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. This represents a 28.87 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CTO Philip Tsai purchased 12,300 shares of Immunome stock in a transaction dated Monday, March 24th. The stock was bought at an average cost of $8.42 per share, with a total value of $103,566.00. Following the completion of the purchase, the chief technology officer now owns 33,300 shares in the company, valued at approximately $280,386. This trade represents a 58.57 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 306,400 shares of company stock valued at $2,322,995. Insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

Several institutional investors have recently modified their holdings of IMNM. GAMMA Investing LLC lifted its holdings in Immunome by 2,822.9% in the 1st quarter. GAMMA Investing LLC now owns 6,138 shares of the company’s stock valued at $410,000 after acquiring an additional 5,928 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Immunome in the 4th quarter worth approximately $70,000. KLP Kapitalforvaltning AS acquired a new stake in Immunome during the fourth quarter valued at approximately $75,000. AlphaQuest LLC boosted its holdings in Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after buying an additional 7,867 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock valued at $91,000 after buying an additional 7,129 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.